Ocean Power Tech, Champions Oncology set to report earnings Monday

Investing.com – Spain stocks were lower after the close on Friday, as losses in the Financial Services & Real Estate, Building & Construction and Chemical, Petroleum & Plastic sectors led shares lower.

At the close in Madrid, the IBEX 35 declined 0.17%.

The best performers of the session on the IBEX 35 were Corporacion Acciona Energias Renovables SA (BME:ANE), which rose 2.15% or 0.44 points to trade at 20.92 at the close. Meanwhile, Redeia Corporacion SA (BME:REDE) added 1.43% or 0.21 points to end at 14.92 and Acciona (BME:ANA) was up 1.42% or 2.50 points to 178.90 in late trade.

The worst performers of the session were Caixabank SA (BME:CABK), which fell 2.50% or 0.25 points to trade at 9.92 at the close. Indra A (BME:IDR) declined 1.62% or 0.80 points to end at 48.58 and Bankinter (BME:BKT) was down 1.56% or 0.22 points to 13.56.

Rising stocks outnumbered declining ones on the Madrid Stock Exchange by 113 to 73 and 24 ended unchanged.

Gold Futures for February delivery was down 0.15% or 6.60 to $4,306.40 a troy ounce. Elsewhere in commodities trading, Crude oil for delivery in January rose 0.16% or 0.09 to hit $57.69 a barrel, while the February Brent oil contract rose 0.05% or 0.03 to trade at $61.31 a barrel.

EUR/USD was unchanged 0.06% to 1.17, while EUR/GBP unchanged 0.23% to 0.88.

The US Dollar Index Futures was up 0.11% at 98.10.

Investing.com – Netherlands stocks were lower after the close on Friday, as losses in the Technology, Healthcare and Oil & Gas sectors led shares lower.

At the close in Amsterdam, the AEX lost 0.78%.

The best performers of the session on the AEX were CVC Capital Partners PLC (AS:CVC), which rose 4.26% or 0.58 points to trade at 14.21 at the close. Meanwhile, Inpost SA (AS:INPST) added 2.72% or 0.27 points to end at 10.19 and Randstad NV (AS:RAND) was up 2.36% or 0.75 points to 32.50 in late trade.

The worst performers of the session were ASM International NV (AS:ASMI), which fell 4.90% or 26.60 points to trade at 516.20 at the close. BE Semiconductor Industries NV (AS:BESI) declined 3.51% or 4.80 points to end at 132.10 and ABN AMRO Group NV (AS:ABNd) was down 3.06% or 0.91 points to 28.83.

Rising stocks outnumbered declining ones on the Amsterdam Stock Exchange by 50 to 49 and 9 ended unchanged.

The AEX Volatility, which measures the implied volatility of AEX options, was unchanged 0.00% to 21.09.

Crude oil for January delivery was up 0.14% or 0.08 to $57.68 a barrel. Elsewhere in commodities trading, Brent oil for delivery in February rose 0.05% or 0.03 to hit $61.31 a barrel, while the February Gold Futures contract fell 0.21% or 9.00 to trade at $4,304.00 a troy ounce.

EUR/USD was unchanged 0.06% to 1.17, while EUR/GBP unchanged 0.24% to 0.88.

The US Dollar Index Futures was up 0.12% at 98.11.

Investing.com -- Actinium Pharmaceuticals Inc (NYSE:ATNM) stock rose 3.7% on Friday following the presentation of new preclinical data for its breast cancer therapy candidate ATNM-400 at the 2025 San Antonio Breast Cancer Symposium.

The company’s Actinium-225 based antibody radioconjugate demonstrated robust anti-tumor activity across multiple breast cancer models, including hormone receptor-positive, triple-negative, and treatment-resistant tumors. The therapy targets an antigen that is overexpressed in breast cancer cells, particularly those resistant to standard treatments like tamoxifen and trastuzumab.

ATNM-400 showed significant tumor growth inhibition in preclinical models while maintaining a favorable tolerability profile. The data revealed that the therapy’s Actinium-225 alpha-emitter payload induced irreversible double-strand DNA breaks, potentially producing localized tumor killing with reduced off-target toxicity compared to antibody drug conjugates.

The company is positioning ATNM-400 as a potential pan-tumor targeted radiotherapy that could address multiple breast cancer subtypes with limited treatment options. Beyond breast cancer, Actinium has previously presented data supporting the therapy’s potential in prostate cancer and non-small cell lung cancer.

Breast cancer remains the most diagnosed cancer among women in the United States, with approximately 316,950 women expected to be diagnosed in 2025. Hormone receptor-positive, HER2-negative breast cancer accounts for 70-75% of cases, representing the largest subtype.

Actinium Pharmaceuticals is developing ATNM-400 as both a monotherapy and in combination with existing treatments, with plans to advance the candidate toward clinical readiness.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com -- Rivian Automotive Inc (NASDAQ:RIVN) stock surged 14% Friday, climbing to $18.70 after Needham analyst Chris Pierce raised his price target on the electric vehicle maker to $23 from $14 while maintaining a Buy rating.

The price target increase follows Rivian’s inaugural Autonomy & AI Day, where the company unveiled its proprietary silicon chips, next-generation autonomy platform, and comprehensive AI integration strategy. Pierce cited increased confidence in Rivian’s positioning in the software-defined vehicle market as a key factor behind the upgraded outlook.

"We reiterate our Buy rating and raise our price target to $23 following RIVN’s AI & Autonomy Day. The event increased our confidence in RIVN’s positioning as software (and now AI) defined vehicles increasingly become industry table stakes, with RIVN’s vertical integration allowing for fuller control driving faster learning and feature iterations across driver interface and autonomy technology, underpinning a durable competitive advantage," Pierce noted.

At the event, Rivian revealed its custom-designed Rivian Autonomy Processor (RAP1) and third-generation Autonomy Compute Module (ACM3), which delivers 1600 sparse INT8 TOPS (Trillion Operations Per Second). The company plans to integrate this technology along with LiDAR into its upcoming R2 models starting in late 2026.

Rivian also announced plans to launch an autonomy subscription service called Autonomy+ in early 2026, priced at either $2,500 as a one-time fee or $49.99 monthly. Additionally, the company introduced its Rivian Assistant, a next-generation voice interface powered by AI that will be available on both first and second-generation R1 vehicles.

Pierce’s updated price target represents a multiple of 20x EV/FY28 estimated adjusted EBITDA, up from 15x previously, reflecting growing enthusiasm for the company’s R2 vehicle ahead of its planned first-half 2026 launch.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Investing.com – Indonesia stocks were higher after the close on Friday, as gains in the Agriculture, Basic Industry and Property sectors led shares higher.

At the close in Jakarta, the IDX Composite Index added 0.41%.

The best performers of the session on the IDX Composite Index were Citatah Tbk (JK:CTTH), which rose 34.57% or 56.00 points to trade at 218.00 at the close. Meanwhile, Abadi Lestari Indonesia Tbk Pt (JK:RLCO) added 25.00% or 110.00 points to end at 550.00 and Bumi Resources Minerals Tbk (JK:BRMS) was up 24.87% or 245.00 points to 1,230.00 in late trade.

The worst performers of the session were Ketrosden Triasmitra PT (JK:KETR), which fell 14.86% or 220.00 points to trade at 1,260.00 at the close. Harapan Duta Pertiwi PT (JK:HOPE) declined 14.53% or 25.00 points to end at 147.00 and Murni Sadar Tbk PT (JK:MTMH) was down 12.95% or 180.00 points to 1,210.00.

Falling stocks outnumbered advancing ones on the Jakarta Stock Exchange by 403 to 295 and 142 ended unchanged.

Shares in Citatah Tbk (JK:CTTH) rose to all time highs; up 34.57% or 56.00 to 218.00. Shares in Abadi Lestari Indonesia Tbk Pt (JK:RLCO) rose to all time highs; gaining 25.00% or 110.00 to 550.00. Shares in Bumi Resources Minerals Tbk (JK:BRMS) rose to all time highs; gaining 24.87% or 245.00 to 1,230.00.

Crude oil for January delivery was up 0.62% or 0.36 to $57.96 a barrel. Elsewhere in commodities trading, Brent oil for delivery in February rose 0.54% or 0.33 to hit $61.61 a barrel, while the February Gold Futures contract rose 0.34% or 14.45 to trade at $4,327.45 a troy ounce.

USD/IDR was up 0.06% to 16,646.90, while AUD/IDR rose 0.04% to 11,107.20.

The US Dollar Index Futures was unchanged 0.00% at 97.99.

Investing.com -- VertiGIS Ltd, a portfolio company of Battery Ventures, has reached an agreement in principle with 1Spatial plc (AIM:SPA) on key terms for a possible cash offer valuing the geospatial software company at approximately £87.1 million.

The possible offer of 73 pence per share represents a 57% premium to 1Spatial’s closing price of 46.5 pence on Wednesday, according to a regulatory announcement released Friday.

The 1Spatial board has indicated it intends to unanimously recommend the offer to shareholders should a firm offer be made, citing attractive valuation and compelling liquidity opportunity not currently available in public markets.

The possible offer has already received support from 1Spatial’s largest shareholders representing 33.8% of issued ordinary share capital.

VertiGIS has secured irrevocable undertakings from Threadneedle Asset Management Limited and Columbia Threadneedle Management Limited for approximately 17.7% of shares, and a non-binding letter of intent from Canaccord Genuity Asset Management for approximately 16.1%.

1Spatial’s board believes the combination would create strategic benefits by aligning complementary product capabilities and customer bases, potentially accelerating adoption of 1Spatial’s technology and broadening international distribution.

Under the Code on Takeovers and Mergers, VertiGIS must announce a firm intention to make an offer by January 9, 2026, or announce it does not intend to proceed.

VertiGIS, headquartered in London, is a leading spatial asset management solutions provider with over 500 employees across 21 offices in 9 countries. The company serves more than 5,000 customers worldwide, primarily in utility, government, telecommunications and infrastructure sectors.

Battery Ventures, which backs VertiGIS, is currently investing from its 14th flagship fund and companion Select Fund II, together capitalized at $3.8 billion, with Battery having raised over $13 billion since inception.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.